Sunovion’s TAAR1 Agonist Brings Something New To CNS Arena
‘Exciting Step Forward’?
Sunovion’s new schizophrenia candidate is generating investor attention given its first-in-class mode of action. Newly published clinical results appear to bear out its promise in a sector where there’s been limited innovation.
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.